Research programme: angiogenesis inhibitors - Boehringer Ingelheim
Alternative Names: BIBF-1000Latest Information Update: 04 Nov 2017
Price :
$50 *
At a glance
- Originator Boehringer Ingelheim; Boehringer Ingelheim Pharma KG
- Class Indoles
- Mechanism of Action Angiogenesis inhibitors; Vascular endothelial growth factor receptor-2 antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Cancer in Austria (PO)
- 04 Nov 2017 No recent reports of development identified for preclinical development in Cancer in Germany (PO)
- 16 Jan 2013 Preclinical development is ongoing in Austria and Germany